A Ten-Year Commitment on Six Months’ Notice: Reading the UK-US Pricing Arrangement 24 Sep 2026

The UK-US arrangement on pharmaceuticals pricing and tariffs represents the most significant change to the UK’s medicines commercial environment in more than a decade. For companies planning launches, placing trials or making the internal case for UK investment, it is worth separating what the arrangement commits to from what it leaves open.

What has been committed

The headline commitments run in two directions. On price and access:

• An increase in the price paid by the NHS for new medicines of up to 25%, delivered through a rise in the NICE cost-effectiveness threshold and the introduction of an updated value set.
• A cap on the VPAG headline payment rate for the remainder of the scheme.

And on the size of the overall market:

• Spending of at least 0.6% of GDP on new medicines by the end of 2036.
• An increase in the proportion of the NHS budget spent on medicines from 10% to 12% over the same period.

Read together, these address both halves of a problem the sector has long described as two separate ones. A threshold increase changes what gets approved for reimbursement; a spend commitment changes the budget that approval draws on. Movement on one without the other has historically produced little.

This is a material improvement on the position of two years ago, and it deserves to be recognised as one.

Three questions it leaves open

The commitments are long-dated, which makes the mechanics of how they are honoured more consequential than the headline figures.

First, measurement. A commitment to spend 0.6% of GDP on branded medicines by 2036 is only as meaningful as the ability to tell whether it is being met. Industry and Government currently publish different assessments of present spend, in part because they count different things — the treatment of VAT alone moves the figure. Until there is an agreed basis of measurement, or an independent one, progress towards the target is a matter of assertion rather than evidence. The same applies in the other direction: when a medicine or a budget is described as unaffordable, that claim can neither be tested nor rebutted.

Second, durability. UK policy on access and adoption is intended to remain consistent with the arrangement through to the mid-2030s. The arrangement itself is terminable at relatively short notice by either party. Companies are therefore being asked to plan capital allocation against a ten-year policy horizon that rests on a considerably shorter commitment. That is not an argument against the arrangement, but it is the first question a well-run investment committee will ask, and the sector does not currently have a good answer to it. What happens to the spend targets, the threshold change and the pilot programme if the arrangement lapses has not been set out.

Third, distribution. An arrangement whose benefits are weighted towards the largest and fastest-growing investors is a rational way to attract inward investment. It is a less obvious fit for the smaller companies whose UK presence is most precarious and whose survival depends most directly on the commercial environment. Whether the benefit reaches them is a separate question from whether the headline numbers improve.

Our view

At our executive forum in July we put a direct question to senior pharmaceutical and biotechnology leaders: in five years’ time, will organisations and investors still prioritise the UK?

The room was near-unanimous on the strengths — a world-class science base, a regulator that has become faster and more willing to engage early, and an NHS data asset few comparable markets can match. It was markedly less confident about conversion. Delegates were consistent that the constraint was not the regulator but the wider system around it, and that the timeline which actually gets modelled is time to patient rather than time to approval.

On that measure, this arrangement addresses the right part of the system. A threshold increase and a payment cap are access measures, not approval measures, and access is where our delegates located the problem.

The other theme from that room is the one this arrangement has not yet resolved. The concern was rarely the direction of policy. It was whether policy would hold long enough to plan against. A delegate’s observation that the UK tends to improve against its own past rather than against the markets it competes with applies here too: the commitments are a genuine improvement on 2024, and they still have to survive contact with a competitive environment where other markets are also moving.

Two things would convert this from an announcement into a planning assumption: an agreed or independent basis for measuring spend against the 0.6% commitment, and a clear statement of what survives if the arrangement does not. Neither is exotic. Both are the difference between a policy a company can model and one it can only hope for.

What to do now

For companies with a UK decision in the next eighteen months, three practical points follow.

Revisit any UK launch case built on the pre-arrangement threshold, since the economics of marginal indications may now look different. Build the durability question into the case explicitly rather than leaving it for the investment committee to raise. And if you are a smaller company, establish early whether the mechanisms that carry the benefit are ones you can actually access, because the headline improvement and the improvement available to you may not be the same number.

PharmaMedic Consultancy works with pharmaceutical and biotechnology companies on regulatory strategy and market access, including UK entry and launch planning. If you would like to discuss what these changes mean for your programme, please contact us at hello@pharmamedic.co.